Ipamorelin

A highly selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin levels.

Normal Protocol

Advanced Protocol

Overview

Also Known As

IPA, NNC 26-0161

Mechanism of Action

Selective ghrelin receptor agonist stimulating GH release from the anterior pituitary. Does not significantly affect cortisol, prolactin, or ACTH at physiological doses.

Product

IPA, NNC 26-0161 vial
Dosing & Administration
Typical protocols and routes

Half-Life

Approximately 2 hours

Administration Routes

subcutaneous

Dosing Protocols

Average: 0.5 mg/day (vial lasts 20 days) — reconstitute 10 mg vial with 2 mL bacteriostatic water, draw 10 units on insulin syringe (marked 1-100). Advanced: 1 mg/day (vial lasts 10 days) — reconstitute 10 mg vial with 1 mL bacteriostatic water, draw 10 units on insulin syringe.
Research
Key findings and status

Key Research Findings

Phase II clinical trials for post-surgical recovery. Demonstrated dose-dependent GH release in human studies. Shown to improve bone mineral content in animal models.
Detailed Information

Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. It is considered one of the safest and most selective GH-releasing peptides, stimulating growth hormone release without significantly affecting cortisol, prolactin, or appetite.

Overview

Ipamorelin is a pentapeptide (five amino acids) that mimics ghrelin and binds to the ghrelin receptor (GHS-R) in the pituitary gland. Unlike other GHRPs, it does not cause significant increases in cortisol, acetylcholine, prolactin, or aldosterone at typical doses, making it highly selective for GH release.

Research Highlights

Clinical trials have demonstrated ipamorelin’s ability to increase GH secretion in a dose-dependent manner. It has been studied for post-surgical recovery, bone density improvement, and as a diagnostic tool for growth hormone deficiency.

Safety & Legal

Side Effects & Warnings

Headache, flushing, dizziness, nausea. Generally mild and transient. Water retention possible.

Legal Status

Research use only
Molecular Data
Chemical properties

Molecular Weight

711.85 g/mol

Amino Acid Sequence

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Quick Facts

Class

GHRP

Research Status

Clinical Trials

Half-Life

Approximately 2 hours

Routes

subcutaneous

Category

Growth Hormone Peptides